Composite Gadolinium Oxide and Yttrium Phosphate Nanoparticles for Managing Cancer Therapy with Magnetic Resonance Imaging
EMSL Project ID
4097
Abstract
This project aims at developing an integrated approach for cancer treatment using combined injectable radioactive nanoparticles and thermally reversible gels. Poly(ethylene glycol)-g-poly(lactic-co-glycolic acid) co-polymers are currently under development at PNNL for use in drug delivery and cancer therapies. These new polymer systems show enhanced drug retention following localized injection in-vivo because they gel at body temperature. Once injected, these gels can therefore be exploited to carry locally high concentrations of therapeutics to the target tissue with greatly reduced risk of systemic effects. Currently Yt90-phosphate nanoparticles are incorporated into the PEG-g-PLGA polymer system for localized radionuclide delivery in cancer therapy. After local injection, however, the precise distribution of radioactive nanoparticles within the target tissue remains uncertain since no direct means of visualization is currently available. To overcome this shortcoming, and facilitate better treatment management, hybrid nanoparticles are being developed that are composed of both Gadolinium oxide and Yt90-phosphate. This EMSL user proposal seeks to test the NMR relaxation properties for these newly developed hybrid particles so that their potential use for managing drug delivery with Magnetic Resonance (MR) imaging can be evaluated. If the hybrid particles have appropriate NMR relaxation properties their incorporation into the PEG-g-PLGA polymer matrix should allow for real time MR imaging of cancer therapies following the injection of the polymer/particle complex. Experimental Design: Non-radioactive analogs containing Yttrium 89 will be synthesized at UW and delivered to PNNL for NMR testing. Samples containing different concentrations of Gd will then be studied with NMR to determine the minimum Gd concentration required for reliable detection in MR imaging experiments. Afterwards a proof-of-principle experiment will then be performed where the injection of a polymer/particle complex is visualized in excised tissue using MR imaging.
Requested Resources: Two week of imaging time on the Varian 500WB is requested for this project.
Proposal Outcomes: The preliminary data acquired through this EMSL user proposal will be published and incorporated into a NIH regular R01 proposal to be submitted by PNNL and UW scientists in Oct 2003.
Project Details
Project type
Capability Research
Start Date
2004-05-16
End Date
2006-04-19
Status
Closed
Released Data Link
Team
Principal Investigator
Team Members